

ASPERGILLUS GM LATERAL FLOW ASSAY



test BENEFITS

- 30 minute run time
- High sensitivity and specificity
- Simplified procedure
- Serum & BAL Capable
- Eliminate batch testing

the PROBLEM

Over 30 million people are at risk of invasive aspergillosis each year because of corticosteroid use or other therapies, and over 300,000 patients develop it annually.

The disease is common in high-risk patients with:

- Hematological malignancies
- Allogeneic HSCT (stem cell transplant)
- Chemotherapy-induced neutropenia
- Solid organ transplant (primarily lung)

real VALUE

- Delivers accurate results in **30 minutes**, reducing time to proper treatment for patients.
- Test at-risk patients more frequently.
- Simplified procedure with minimal specimen preparation.
- Eliminate delays in diagnosis due to batch testing.

true PERFORMANCE

The sona AGM LFA displays high performance in both specimen types:

<u>Serum</u>	Asp Ag EIA		
Asp GM		Pos	Neg
LFA Assay	Pos	26	1
	Neg	6	116

lock to locate locate	Cl
% Agreement Pos 81% 64% - 9	93%
% Agreement Neg 99% 95% - 99	9.9%

<u>BAL</u>	Asp Ag EIA		
Asp GM		Pos	Neg
LFA Assay	Pos	25	3
LI A Assay	Neg	3	48

BAL	Calculated	95% CI
% Agreement Pos	89%	72% - 98%
% Agreement Neg	94%	84% - 99%

simple PROCEDURE



